Halozyme Therapeutics, Inc.
US ˙ NasdaqGS ˙ US40637H1095

SecurityHALO / Halozyme Therapeutics, Inc.
InstitutionStrs Ohio
Latest Disclosed Ownership27,775 shares
Latest Disclosed Value $ 1,795,098
Strs Ohio reports 899.46% increase in ownership of HALO / Halozyme Therapeutics, Inc.

On April 24, 2026 - Strs Ohio filed a 13F-HR form disclosing ownership of 27,775 shares of Halozyme Therapeutics, Inc. (US:HALO) valued at $1,795,098 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 2, 2026 disclosing 2,779 shares of Halozyme Therapeutics, Inc.. This represents a change in shares of 899.46% during the quarter. The current value of the position is $1,986,746 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-04-24 2026-03-31 13F HALOZYME THERAPEUTICS COM_STK 40637H109 27,775 24,996 899.46 1,795 859.89 0.0071
2026-02-02 2025-12-31 13F HALOZYME THERAPEUTICS COM_STK 40637H109 2,779 -151 -5.15 187 -12.62 0.0007
2025-10-30 2025-09-30 13F HALOZYME THERAPEUTICS COM_STK 40637H109 2,930 -25,069 -89.54 215 -85.30 0.0008
2025-08-04 2025-06-30 13F HALOZYME THERAPEUTICS COM_STK 40637H109 27,999 -2,001 -6.67 1,457 -23.93 0.0054
2025-05-28 2025-03-31 13F HALOZYME THERAPEUTICS COM_STK 40637H109 30,000 -3,800 -11.24 1,914 18.51 0.0080
2025-05-28 2024-12-31 13F HALOZYME THERAPEUTICS COM_STK 40637H109 33,800 2,100 6.62 1,616 -10.97 0.0064
2024-11-01 2024-09-30 13F HALOZYME THERAPEUTICS COM_STK 40637H109 31,700 0 0.00 1,815 9.34 0.0070
2024-08-05 2024-06-30 13F HALOZYME THERAPEUTICS COM_STK 40637H109 31,700 -2,400 -7.04 1,660 165,800.00 0.0066
2024-05-13 2024-03-31 13F HALOZYME THERAPEUTICS COM_STK 40637H109 34,100 -4,100 -10.73 1 0.00 0.0055
2024-01-30 2023-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 38,200 -1,800 -4.50 1 0.00 0.0059
2023-10-26 2023-09-30 13F/A-1 HALOZYME THERAPEUTICS COM 40637H109 40,000 -2,200 -5.21 2 0.00 0.0068
2023-10-26 2023-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 40,000 -2,200 2 0.0068
2023-07-31 2023-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 42,200 12,000 39.74 2 0.00 0.0064
2023-08-02 2023-03-31 13F/A-2 HALOZYME THERAPEUTICS COM 40637H109 30,200 3,700 13.96 1 0.00 0.0050
2023-08-02 2023-03-31 13F/A-1 HALOZYME THERAPEUTICS COM 40637H109 30,200 1
2023-04-27 2023-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 30,200 3,700 1 0.0060
2023-01-26 2022-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 26,500 -17,500 -39.77 2 -99.94 0.0068
2022-10-27 2022-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 44,000 17,400 65.41 1,739 48.63 0.0083
2022-07-25 2022-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 26,600 4,100 18.22 1,170 30.43 0.0053
2022-04-21 2022-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 22,500 -28,900 -56.23 897 -56.58 0.0033
2022-01-24 2021-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 51,400 2,500 5.11 2,066 3.87 0.0072
2021-10-22 2021-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 48,900 0 0.00 1,989 -10.41 0.0075
2021-07-26 2021-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 48,900 31,500 181.03 2,220 206.21 0.0080
2021-04-23 2021-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 17,400 -800 -4.40 725 -6.69 0.0027
2021-01-25 2020-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 18,200 1,700 10.30 777 79.45 0.0030
2020-12-14 2020-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 16,500 -600 -3.51 433 -5.46 0.0018
2020-07-23 2020-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 17,100 -9,400 -35.47 458 -3.78 0.0020
2020-04-23 2020-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 26,500 -39,400 -59.79 476 -59.25 0.0025
2020-01-24 2019-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 65,900 -4,200 -5.99 1,168 7.45 0.0049
2019-10-21 2019-09-30 13F/A-1 HALOZYME THERAPEUTICS COM 40637H109 70,100 0 0.00 1,087 -9.72 0.0048
2019-10-21 2019-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 70,100 4,200 1,087 4,811.1223
2019-07-25 2019-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 70,100 3,400 5.10 1,204 12.21 0.0054
2019-04-19 2019-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 66,700 0 0.00 1,073 10.05 0.0049
2019-01-23 2018-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 66,700 1,100 1.68 975 -18.14 0.0049
2018-10-19 2018-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 65,600 0 0.00 1,191 7.69 0.0052
2018-08-06 2018-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 65,600 61,300 1,425.58 1,106 1,216.67 0.0048
2018-04-20 2018-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 4,300 500 13.16 84 10.53 0.0004
2018-01-23 2017-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 3,800 3,800 76 0.0003
2016-04-21 2016-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 0 -6,100 -100.00 0 -100.00
2016-01-28 2015-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 6,100 -7,200 -54.14 105 -41.01 0.0005
2015-10-21 2015-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 13,300 7,500 129.31 178 36.92 0.0008
2015-08-04 2015-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 5,800 5,800 130 0.0006
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.